EGFR Exon 20 insertion in lung adenocarcinomas among Hispanics (Geno1.2-CLICaP)

The identification of epidermal growth factor receptor (EGFR) mutations has transformed our approach towards the use of targeted therapies in Non-small cell lung cancer (NSCLC) [1 –3]. Lung cancers harboring exon 20 insertions in EGFR (exon20 in.) make up one genotype-defined subset of lung cancer that is in need of an effective targeted treatment approach [4,5]. EGFR exon20 in. were identified contemporaneously with the more common Tyrosine kinase inhibitors (TKI)-sens itive mutations in exons 19 and 21 of EGFR [6,7].

Source: Lung Cancer - October 9, 2018 Category: Cancer & Oncology Authors: Andr és F. Cardona, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Helano C. Freitas, Sara T. Granados, Omar Castillo, George Oblitas, Luis Corrales, Christian D. Castro, Alejandro Ruiz-Patiño, Claudio Martín, María Angelina Pérez, Lisde González, L Source Type: research